Psychotropic drugs induced weight gain: A review of the literature concerning epidemiological data, mechanisms and management;Prise de poids pharmaco-induite par les psychotropes et sa prise en charge: Revue des données de la littérature

Encephale

Volumn 31, Issue 4 I, 2005, Pages 507-516

  Ruetsch, O ^a   Viala, A ^a   Bardou, H ^a   Martin, P ^a   Vacheron, M N ^a  

^a CENTRE HOSPITALIER SAINTE ANNE   (France)

Author keywords

Epidemiology; Management; Psychotropic medication; Weight gain

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLESTEROL; CLOMIPRAMINE; CLOZAPINE; CYTOKINE; DOXEPIN; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HORMONE; IMIPRAMINE; LEPTIN; LITHIUM; MAPROTILINE; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; SEROTONIN UPTAKE INHIBITOR; TRIACYLGLYCEROL; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; TUMOR NECROSIS FACTOR; UNINDEXED DRUG; VALPROIC ACID;

APPETITE DISORDER; BEHAVIOR THERAPY; BIPOLAR DISORDER; BLOOD PRESSURE REGULATION; BODY MASS; BODY WEIGHT DISORDER; CANCER; CEREBROVASCULAR ACCIDENT; DEATH; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DIETARY INTAKE; DISEASE SEVERITY; DYSLIPIDEMIA; ENERGY BALANCE; FAT INTAKE; FEEDING; GENETIC PREDISPOSITION; HOSPITALIZATION; HUMAN; HYPEROSMOLAR COMA; HYPERTENSION; HYPOTHALAMUS; IMPAIRED GLUCOSE TOLERANCE; INSULIN LIKE ACTIVITY; ISCHEMIC HEART DISEASE; MAINTENANCE THERAPY; MENTAL PATIENT; METABOLIC RATE; MORALITY; MORBIDITY; NUTRITIONAL STATUS; OBESITY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PATIENT COUNSELING; PHYSICAL ACTIVITY; PSYCHIATRIST; PSYCHOSOCIAL ENVIRONMENT; RELAPSE; RESPIRATORY TRACT DISEASE; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SOCIAL ASPECT; SWEETNESS; WEIGHT GAIN;

EID: 27244437874     PISSN: 00137006     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0013-7006(05)82412-1     Document Type: Review

References (75)

1. ADDINGTON J, MANSLEY C, ADDINGTON D. Weight gain in first episode psychosis. Can J Psychiatry 2003; 48 (4): 272-6.
2. AFERO (Association Française d'Études et de Recherches sur l'Obésité), SNDLF (Société de Nutrition et de Diététique de Langue Française), ALFEDIAM (Association de Langue Française pour l'Étude du Diabète et des Maladies Métaboliques). Recommandations pour le diagnostic, la prévention et le traitement des obésités en France. Cah Nutr Diet 1998; 33 (Suppl 1): 1-48.
3. ALLISON DB, MENTORE JL, HEO M et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999; 156 (11): 1686-96.
4. ALLISON DB, CASEY DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001; 62 (Suppl 7): 22-31.
5. AMERICAN DIABETES ASSOCIATION, AMERICAN PSYCHIATRIC ASSOCIATION, AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS, NORTH AMERICAN ASSOCIATION FOR THE STUDY OF OBESITY. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004; 65 (2): 267-72.
6. ATMACA M, KULOGLU M, TEZCAN E et al. Weight gain and serum leptin levels in patients on lithium treatment (abstract). J Clin Psychiatry 2002; 46 (2): 67-9.
7. ATMACA M, KULOGLU M, TEZCAN E et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics (abstract). J Clin Psychiatry 2003; 64 (5): 598-604.
8. BALL MP, COONS VB, BUCHANAN RW. A program for treating olanzapine-related weight gain (abstract). Psychiatr Serv 2001; 52 (7): 967-9.
9. BASILE VS, MASELLIS M, MCINTYRE RS et al. Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. J Clin Psychiatry 2001; 62: 45-66.
10. BECH P, VENDSBORG PB, RAFAELSEN OJ. Lithium maintenance treatment of manic-melancholic patients: its role in the daily routine. Acta Psychiat Scand 1976; 53: 70-81.
11. BERKEN GH, WEINSTEIN DO, STERN WC. Weight gain: a side-effect of tricyclic antidepressants. J Affect Disord 1984; 7: 133-8.
12. BIRT J. Management of weight gain associated with antipsychotics. Ann Clin Psychiatry 2003; 15 (1): 49-58.
13. BLIN O, MICALLEF J. Antipsychotic-associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001; 62 (Suppl 7): 11-21.
14. BOWDEN CL, CALABRESE JR, MCELROY S et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry 2000; 57: 482-9.
15. BRADY KT. Weight gain associated with psychotropic drugs. South Med J 1989; 82(5): 611-7.
16. BROMEL T, BLUM WF, ZIEGLER A et al. Serum leptin levels increase rapidly after initiation of clozapine therapy (abstract). Mol Psychiatry 1998; 3 (1): 76-80.
17. BUIS W. Patients' opinions concerning side effects of depot neuroleptics. Am J Psychiatry 1992; 149 (6): 844-5.
18. CALABRESE JR, GOETHE JW, KAYSER A et al. Adverse events in 583 valproate-treated patients. Depression 1996; 3: 257-62.
19. CALABRESE JR, SUPPES T, BOWDEN CL et al. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. J Clin Psychiatry 2000; 61 (11): 841-50.
20. CARO JJ, WARD A, LEVINTON C et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis (abstract). J Clin Psychiatry 2002; 63 (12): 1135-9.
21. CASEY DE, ZORN SH. The pharmacology of weight gain with antipsychotics. J Clin Psychiatry 2001; 62 (Suppl 7): 4-10.
22. CASSUTO D. Épidémiologie, physiopathologie, diagnostic, complications, traitement de l'obésité. Impact Internat 1994; 14: 243-52.
23. COHEN D. Atypical antipsychotics and new onset diabetes mellitus: an overview of the literature (abstract). Pharmacopsychiatry 2004; 37 (1): 1-11.
24. EDER U, MANGWETH B, EBENBICHLER C et al. Association of olanzapine-induced weight gain with an increase in body fat (abstract). Am J Psychiatry 2001; 158 (10): 1719-22.
25. FADEL J, BUBSER M, DEUTCH AY. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J Neurosci 2002; 22 (15): 6742-6.
26. FAVA M. Weight gain and antidepressant. J Clin Psychiatry 2000; 61 (Suppl 11): 37-41.
27. FERNSTROM MH, EPSTEIN LH, SPIKER DG etal. Resting metabolic rate is reduced in patients treated with antidepressants. Biol Psychiatry 1985; 20: 692-5.
28. FONTAINE KR, HEO M, HARRIGAN EP et al. Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatr Res 2001; 101: 277-88.
29. GANGULI R. Weight gain associated with antipsychotic drugs. J Clin Psychiatry 1999; 60 (Suppl 21): 20-4.
30. GARLAND EJ, REMICK RA, ZIS AP. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988; 8 (5): 323-30.
31. GIANFRANCESCO FD, GROGG AL, MAHMOUD RA et al. Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: finding from a large health plan database. J Clin Psychiatry 2002; 63 (10): 920-30.
32. GITLIN MJ, COCHRAN SD, JAMISON KR. Maintenance lithium treatment: side effects and compliance. J Clin Psychiatry 1989; 50 (4): 127-31.
33. GOLDMAN LS. Medical illness in patients with schizophrenia. J Clin Psychiatry 1999; 60 (Suppl 21): 10-5.
34. GUIDE GRAND PUBLIC. « La Santé vient en Mangeant, le Guide Alimentaire pour Tous », novembre 2002, et le document d'accompagnement destiné aux professionnels de santé. Éditions Lenglet, 2003.
35. HAGG S, JOELSSON L, MJORNDALT et al. Prevalence of diabetes and impaired glucose tolérance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications. J Clin Psychiatry 1998; 59 (6): 294-9.
36. HAGG S, SODERBERG S, AHREN B et al. Leptin concentrations are increased in subjects treated with clozapine or conventionnal antipsychotics. J Clin Psychiatry 2001; 62 (11): 843-8.
37. HARRIS EC, BARRACLOUGH B. Excess mortality of mental disorder. Br J Psychiatry 1998; 173: 11-53.
38. HENDERSON DC, CAGIERO E, GRAY C et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five year naturalistic study. Am J Psychiatry 2000; 157 (6): 975-81.
39. HINZE-SELCH D, SCHULD A, KRAUS T et al. Effects of antidepressants on weight and on the plasma levels of leptin, TNF alpha and soluble TNF receptors: a longitudinal study in patients treated with amitriptyline or paroxetine (abstract). Neuropsychopharmacology 2000; 23 (1): 13-9.
40. KAWACHI I. Physical and psychological consequences of weight gain. J Clin Psychiatry 1999; 60 (Suppl 21): 5-9.
41. KECK PE, MCELROY SL. Bipolar disorder, obesity and pharmacotherapy- associated weight gain. J Clin Psychiatry 2003; 64 (12): 1426-35.
42. KELLY DL, KREYENBUHL J, LOVE RC et al. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine or quetiapine. J Clin Psychiatry 2003; 64 (9): 1133-4.
43. KRAUS T, HAACK M, SCHULD A et al. Body weight and leptin plasma levels during treatment with antipsychotic drug (abstract). Am J Psychiatry 1999; 156 (2): 312-4.
44. KRAUS T, HAACK M, SCHULD A et al. Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine (abstract). Pharmacopsychiatry 2002; 35 (6): 220-5.
45. LEIBOVITZ HE. Metabolic consequences of atypical antipsychotic drugs. Psychiatr Quater 2003; 74 (3): 277-90.
46. LINDENMAYER JP, NATHAN AM, SMITH RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001; 62 (Suppl 23): 30-8.
47. LINDENMAYER JP, CZOBORP, VOLAVKA J et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160 (2): 290-6.
48. LITTRELL KH, HILLIGOSS NM, KIRSHNER CD. The effects of an educational intervention on antipsychotic-induced weight gain (abstract). J Nurs Scholarsh 2003; 35 (3): 237-41.
49. LUND BC, PERRY PJ, BROOKS JM et al. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension. Arch Gen Psychiatry 2001; 58: 1172-6.
50. McELROY SL, FRYE MA, SUPPES T et al. Correlates of overweight and obesity in 644 patients with bipolar disorder (abstract). J Clin Psychiatry 2002; 63 (3): 207-13.
51. McINTYRE RS, MANCINI MA, BASILE VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001; 62 (Suppl 23): 23-9.
52. McINTYRE RS, MANCINI DA, BASILE VS et al. Antipsychotic-induced weight gain: bipolar disorder and leptin (abstract). J Clin Psychopharmacol 2003; 23 (4): 323-7.
53. MENZA M, VREELAND B, MINSKY S et al. Managing atypical antipsychotic-associated weight gain: 12-months data on a multimodal weight control program. J Clin Psychiatry 2004; 65 (4): 471-7.
54. MOGA M, VAILLE-PERRET E, MULLIEZ A et al. Étude de la prise de poids sous risṕridone, olanzapine, amisulpride, chez des patients atteints de schizophrénie. Ann Med Psychol 2004; 162: 128-33.
55. MONTELEONE P, FABRAZZO M, TORTORELLA A et al. Pronounced early increase in circulating leptin predicts a lower weight gain during clozapine treatment (abstract). J Clin Psychopharmacol 2002; 22 (4): 424-6.
56. NEWCOMER JW, HAUPT DW, FUCETOLA R et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia (abstract). Arch Gen Psychiatry 2002; 59 (4): 337-45.
57. PROGRAMME NATIONAL NUTRITION SANTÉ. INPES (Institut National de Prévention et d'Éducation pour la Santé). Le disque de calcul de l'indice de masse corporelle chez l'adulte, septembre 2003.
58. PYLVANEN V, KNIP M, PAKARINEN A et al. Serum insulin and leptin levels in valproate-associated obesity (abstract). Epilepsia 2002; 43 (5): 514-7.
59. RYAN MC, FLANAGAN S, KINSELLA U et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia (abstract). Life Sci 2004; 74 (16): 1999-2008.
60. RUSELL JM, MACKELL JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drug 2001; 15 (7): 537-51.
61. SACHS GS, GUILLE C. Weight gain associated with use of psychotropic medications. J Clin Psychiatry 1999; 60 (Suppl 21): 16-9.
62. STIP E, TRANULIS C, LEGARE N et al. Les médicaments antipsychotiques, facteurs de risque de diabète. Presse Med 2003; 32: 1612-7.
63. TAYLOR DM, McASKILL R. Atypical antipsychotics and weight gain: a systematic review. Acta Psychiatr Scand 2000; 101: 416-32.
64. THEISEN FM, CICHON S, LINDEN A et al. Clozapine and weight gain. Am J Psychiatry 2001; 158 (5): 816.
65. THONNARD-NEUMANN E. Phenothiazines and diabetes in hospitalized women. Am J Psychiatry 1968; 124 (7): 978-82.
66. UMBRICHT D, FLURY H, BRIDLER R. Cognitive behavior therapy for weight gain. Am J Psychiatry 2001; 158 (6): 971.
67. VREELAND B, MINSKY S, MENZA M. A program for managing weight gain associated with atypical antipsychotics (abstract). Psychiatr Serv 2003; 54 (8): 1155-7.
68. VENDSBORG PB, BECH P, RAFAELSEN OJ. Lithium treatment and weight gain. Acta Psychiatr Scand 1976; 53: 139-47.
69. VERROTTI A, BASCIANIF, MORRESIS et al. Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology 1999; 53: 230-2.
70. WEIDEN PJ, MACKELL JA, MCDONNELL DD. Obesity as a risk factor for antipsychotic noncompliance (abstract). Schizophr Res 2004; 66 (1): 51-7.
71. WETTERLING T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Safety 2001; 24: 59-73.
72. WIRSHING DA, WIRSHING WC, KYSAR L et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999; 60 (6): 358-63.
73. WIRSHING DA, BOYD JA, MENG LR et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63 (10): 856-65.
74. ZHANG ZJ, YAO ZJ, LIU W et al. Effects of antipsychotics on fat deposition and changes in leptin and insuline levels. Magnetic resonance imaging study of previously untreated people with schizophrenia (abstract). Br J Psychiatry 2004; 184: 58-62.
75. ZIMMERMANN U, KRAUS T, HIMMERICH H et al. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003; 37: 193-220.